Research programme: CD26 antigen antagonists - Nuada Pharmaceuticals

Drug Profile

Research programme: CD26 antigen antagonists - Nuada Pharmaceuticals

Alternative Names: FF1

Latest Information Update: 08 Feb 2008

Price : $50

At a glance

  • Originator Nuada Pharmaceuticals
  • Developer Nuada Pharmaceuticals (CEASED)
  • Class
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 Mar 2004 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)
  • 31 Mar 2004 Nuada Pharmaceuticals is seeking a collaborative partner for the programme (http://www.nuadapharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top